產(chǎn)品中心
人腫瘤壞死因子α(TNFa)酶聯(lián)免疫吸附檢測(cè)試劑盒
ELK1190 規(guī)格： |
 價(jià)格： |
|---|---|
| 48T | ￥1680.00 |
| 96T | ￥2400.00 |
下載說(shuō)明 ①Overview 文獻(xiàn)
日期：2021-10-20
IF：1.73標(biāo)準(zhǔn)曲線
| Concentration (pg/mL) | OD | Corrected OD |
|---|---|---|
| 1000.00 | 2.214 | 2.086 |
| 500.00 | 1.784 | 1.656 |
| 250.00 | 1.243 | 1.115 |
| 125.00 | 0.872 | 0.744 |
| 62.50 | 0.546 | 0.418 |
| 31.25 | 0.325 | 0.197 |
| 15.63 | 0.240 | 0.112 |
| 0.00 | 0.128 | 0.000 |
精密度
Intra-assay Precision (Precision within an assay)：CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays)：CV%<10%
Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.
回收率
Matrices listed below were spiked with certain level of recombinant TNFa and the recovery rates were calculated by comparing the measured value to the expected amount of TNFa in samples.
| Matrix | Recovery range | Average |
|---|---|---|
| serum(n=5) | 83-95% | 89% |
| EDTA plasma(n=5) | 88-102% | 95% |
| Heparin plasma(n=5) | 79-97% | 88% |
線性
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of TNFa and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Matrix | 1:2 | 1:4 | 1:8 | 1:16 |
|---|---|---|---|---|
| serum(n=5) | 87-96% | 91-101% | 87-98% | 89-103% |
| EDTA plasma(n=5) | 84-94% | 85-103% | 94-105% | 92-101% |
| Heparin plasma(n=5) | 88-104% | 84-98% | 95-105% | 88-102% |
關(guān)閉
在線咨詢(xún)
Online consultation
-
在線咨詢(xún)
-
技術(shù)支持
關(guān)注微信公眾號(hào)
關(guān)閉
